Eyepoint Pharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States, China, and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company's pipeline leverages its Durasert technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Eyepoint Pharmaceuticals Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Eyepoint Pharmaceuticals Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Eyepoint Pharmaceuticals Inc Competitors
Eyepoint Pharmaceuticals Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans